This company is a Bay area company that's most important product
is in phase III testing in Taiwan for the treatment of Hepititus
B, which is one of the most difficult to treat and prevelant
especially in this region, including a massive problem in China.
Taiwan currently has a 17% CHB infection rate.
They have recently taken a beating with a report on this test in
Taiwan, when the stock took a dive from 13 to 7.5. But the stock
watcher who issued this downgrade really didn't look at the whole
study. The results were much better than he realized and the gov't
of Taiwan is going to request that the drug be introduced in the
first quarter of 97 due to the need to address the Hepatitus threat
in their country.
Drug name is Zadaxin. It has shown no systemic or toxic side effects.
China's approval is on track for Sept based on very significant
results from a 1 year test with over 150 subjects.
Schering Plough KK (japanese sub) will begin tests (III) in Sept
and the market for this drug in the Asian market alone is staggering. |
